Vardenafil for the treatment of erectile dysfunction in men with diabetes.
- Author:
Xiaoxiong WANG
1
Author Information
1. Department of Urology, Chinese PLA General Hospital, Beijing 100853, China.
- Publication Type:Journal Article
- MeSH:
Diabetes Complications;
Erectile Dysfunction;
drug therapy;
etiology;
Humans;
Imidazoles;
therapeutic use;
Male;
Phosphodiesterase Inhibitors;
therapeutic use;
Piperazines;
therapeutic use;
Sulfones;
therapeutic use;
Surveys and Questionnaires;
Treatment Outcome;
Triazines;
therapeutic use;
Vardenafil Dihydrochloride
- From:
National Journal of Andrology
2004;10(10):794-797
- CountryChina
- Language:Chinese
-
Abstract:
The prevalence of erectile dysfunction (ED) is higher in diabete patients than in non-diabete men. Moreover, the treatment of ED is more challenging in men with diabetes. Vardenafil, a novel and highly selective phosphodiesterase 5 inhibitor, is the first line therapy for the broad ED population. Recent large-scale clinical trials indicated that vardenafil improved erectile function in ED men with diabetes regardless of the baseline ED severity and plasma HbA1c levels, and it was generally well tolerated.
